Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Merck Group
Acquired Company
Silence Therapeutics plc
Darmstadt
LondonBiotechnologyHealth CareLife ScienceBiotechnologyHealth CareTherapeuticsDescription
Merck is expanding its rare disease business by acquiring Silence Therapeutics for $1.1 billion. The deal, which values Silence at $20 per share, aims to strengthen Merck's capabilities in treating targeted specialty diseases. The acquisition has been approved and is expected to finalize in the first quarter of 2027. This move follows Merck's recent acquisitions in the biotechnology sector.
Fundz sees it the moment Merck Group makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Silence Therapeutics plc?
Silence Therapeutics plc was acquired by Merck Group, based in Darmstadt. The deal was reported on October 19, 2026. Merck Group is a leading science and technology company in the pharmaceutical and chemical sectors. They focus on developing innovative products and solutions across various industries. Merck Group is privately held and operates in Biotechnology.
When did Merck Group acquire Silence Therapeutics plc?
Merck Group's acquisition of Silence Therapeutics plc was reported on October 19, 2026. Merck is expanding its rare disease business by acquiring Silence Therapeutics for $1.1 billion. The deal, which values Silence at $20 per share, aims to strengthen Merck's capabilities in treating targeted specialty diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Silence Therapeutics plc do?
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA technology. It is publicly traded (SLN), operating in Biotechnology, and is based in London.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.